Clinicopathological Correlation
Transcript of Clinicopathological Correlation
-
7/30/2019 Clinicopathological Correlation
1/22
CLINICOPATHOLOGICAL
CORRELATION
-
7/30/2019 Clinicopathological Correlation
2/22
CLINICOPATHOLOGICAL CORRELATION
-
7/30/2019 Clinicopathological Correlation
3/22
Asthma?
Chronic relapsing inflammatory disordercharacterized by hyperactive airwaysleading to episodic, reversible
bronchoconstriction owing to increasedresponsiveness of the tracheobronchialtree to various stimuli
-
7/30/2019 Clinicopathological Correlation
4/22
Extrinsic(immune mediated) Asthma 70%
Initiated by type 1 hypersensivityreaction induced by exposure toextrinsic antigen.
Pathogenesis:
In the airway initial sensitizationto antigen (allergen) withstimulation of TH2 type T cells andproduction of cytokines (IL-4, IL- 5,and IL-13).
IgE-mediated reaction to inhaledallergens elicits:
1. acute response (within minutes)
2. a late phase reaction (after 4-8hours)
Intrinsic (non immune mediated) Asthma 30%
Initiated by diverse,non-immune mechanisms,including:
1. ingestion of aspirin
2. pulmonary infections,
3. cold
4. inhaled irritant
5. stress6. exercise.
CLASSIFICATION OF ASTHMA
-
7/30/2019 Clinicopathological Correlation
5/22
Extrinsic(immune mediated) Asthma
-
7/30/2019 Clinicopathological Correlation
6/22
Acute-phase response
Begin 30 to 60 minutes after inhalation of antigen.
Mast cells on the mucosal surface are activated.
Mediator produced are : Leukotrienes C4, D4 & E4 (induce BRONCHOSPASM, vascular permeability
&MUCOUS PRODUCTION) Prostaglandins D2, E2, F2 (induce BRONCHOSPASM and vasodilatation)
Histamine ( induce bronchospasm and increased vascular permeability)
Platelet-activating factor (cause aggregation of platelets and release ofhistamine)
Mast cell tryptase (inactivate normal bronchodilator).
Mediators induce BRONCHOSPASM, vascular permeability &MUCOUS PRODUCTION.
-
7/30/2019 Clinicopathological Correlation
7/22
Late phase reaction:
RECRUITMENT OF LEUKOCYTES mediated by product of
mast cells including:
1. Eosinophil and neutophil chemotactic factors2 . IL-4 & IL-5 and induceTH2 subset ofCD4+ T cells
3. Platelet-activating factor
4. Tumor necrosis factor.
Other cell types are involved: activated epithelial cells,macrophages and smooth muscle.
-
7/30/2019 Clinicopathological Correlation
8/22
Late phase reaction:
The arrival of leukocytes at the site of mast cell degranulation leadto:
1. RELEASE OF MORE MEDIATORS to activate more mast cells
2. Cause EPITHELIAL CELL DAMAGE .
Eosinophils produce major basic protein, EOSINOPHILICCATIONIC PROTEIN AND EOSINOPHIL PEROXIDASE( TOXIC TO EPITHELIAL CELLS).
These amplify and sustains injury without additionalantigen.
-
7/30/2019 Clinicopathological Correlation
9/22
Intrinsic (non immune mediated) Asthma
-
7/30/2019 Clinicopathological Correlation
10/22
Triggered by respiratory tract infection includingviruses and inhaled air pollutants e.g. sulfurdioxide, ozone.
Positive family history is uncommon. Serum IgEnormal. Noother associated allergies. Skin test negative. HYPERIRRITABILITYof bronchial tree. Subtypes:
1. Drug-induced asthma.2. Occupational asthma.
-
7/30/2019 Clinicopathological Correlation
11/22
PATHOGENESIS
Drug induced:
E.g Aspirin
Inhibits cyclooxygenase pathway without affecting
lipoxygenase route thus bronchoconstrictor
leukotrienes are more elaborated
-
7/30/2019 Clinicopathological Correlation
12/22
-
7/30/2019 Clinicopathological Correlation
13/22
The classic acute asthmatic attack lasts up toseveral hours
In its most severe form, status asthmaticus, the
severe acute paroxysm persists for days and evenweeks, and under these circumstances airflowobstruction might be so extreme as to causesevere cyanosis and even death
The clinical diagnosis is aided by thedemonstration of an increase in airflowobstruction (from baseline levels), difficulty withexhalation (prolonged expiration, wheeze),
With appropriate therapy to relieve the attacks,most individuals with asthma are able to maintaina productive life.
-
7/30/2019 Clinicopathological Correlation
14/22
Clinical findings
difficulty in breathing and wheezing.
decreased FEV1
Suggests a lung disease. The decreased FEV1implicates an obstructive lung disease
Acute phase reaction(Mediators induce
BRONCHOSPASM, vascular permeability &
MUCOUS PRODUCTION)
d ki ll di i f h
-
7/30/2019 Clinicopathological Correlation
15/22
stopped taking all medication for the
past several weeks
With appropriate therapy to relieve the
attacks, most individuals with asthma are
able to maintain a productive life.
Patient could not afford medication
-
7/30/2019 Clinicopathological Correlation
16/22
he could barely talk and was breathing 30times/minute. Physical exam was remarkablefor rare wheezing and markedly diminishedbreath sounds. Arterial blood gases pH = 6.9,
pCO2 = 88, pO2 = 35. While awaiting therapy thepatient suffered a cardiac arrest and could notbe resuscitated.
Wheezing, diminished breath sounds, respiratory
acidosis further implicate a lung disease, inaddittion to which, the autopsy showed grossfindings limited to the respiratory tract.
t d t th ER ith
-
7/30/2019 Clinicopathological Correlation
17/22
presented to the ER with severeshortness of breath of 8 hours
duration. status asthmaticus, the severe acute
paroxysm persists for days and even weeks,
and under these circumstances airflowobstruction might be so extreme as to cause
severe cyanosis and even death
-
7/30/2019 Clinicopathological Correlation
18/22
Lab dx
bronchial lumen contains large amounts of mucus, a moderate numberof macrophages and eosinophilic leukocytes.
The bronchiole is plugged with mucus and cellular debris.
The bronchiolar epithelium is intact, but there is a marked inflammatoryinfiltrate in the bronchiolar wall.
The basement membrane is thickened and hyalinized. The submucousglands are increased in size.
The smooth muscle of the bronchial wall appears hypertrophic.Eosinophils, some PMNs, lymphocytes and plasma cells are seen in thebronchial wall. These changes of the bronchial wall are typical forasthma.
-
7/30/2019 Clinicopathological Correlation
19/22
Beta agonists
METHYLXANTHINE DRUGS
ANTIMUSCARINIC AGENTS
CORTICOSTEROIDS
CROMOLYN & NEDOCROMIL
LEUKOTRIENE PATHWAY INHIBITORS
f ff f b d i i t Th
-
7/30/2019 Clinicopathological Correlation
20/22
few puffs of b-adrenergic agonist. The
patient was prescribed a b-adrenergic
inhaler Beta-adrenergic receptors are coupled to the stimulatory G protein.
activates adenylyl cyclase, which catalyzes the production of cyclicadenosine monophosphate (cAMP).
In the lung, cAMP causes a decrease in the intracellular calcium
concentration and, via activation of protein kinase A, both inactivatesmyosin light chain kinase and activates myosin light chain phosphorylase.
In addition, beta-2 agonists open large conductance calcium-activatedpotassium channels and thereby tend to hyperpolarize airway smoothmuscle cells.
The combination of decreased intracellular calcium, increased membrane
potassium conductance, and decreased myosin light chain kinase activity leads to SMOOTH MUSCLE RELAXATION and BRONCHODILATION.
Early phase reaction
-
7/30/2019 Clinicopathological Correlation
21/22
patient continued to experience
episodes of breathlessness Corticosteroids enhance the beta-adrenergic response to relieve the
muscle spasm.
They also act by reversing the mucosal edema, decreasing vascularpermeability by vasoconstriction, and inhibiting the release of LTC4 andLTD4.
Corticosteroids inhibit the late phase reaction by inhibiting theinflammatory response and interfering with chemotaxis. This action maybe due to the inhibition of LTB4 release. The eosinopenic effect ofcorticosteroids may help to prevent the cytotoxic effect of the majorbasic protein and other inflammatory mediators released fromeosinophils.
By blocking the late reaction, they prevent the increased airwayreactivity observed with late bronchial reactions.
LATE PHASE REACTION(RELEASE OF MORE MEDIATORS to activate more mast cells 2. Cause EPITHELIAL CELLDAMAGE )
-
7/30/2019 Clinicopathological Correlation
22/22